Squamous metaplasia of the canaliculi associated with 5-fluorouracil: A clinicopathologic case report

Ophthalmology

Volumn 109, Issue 12, 2002, Pages 2359-2361

  Agarwal, Madhu R ^a   Esmaeli, Bita ^b   Burnstine, Michael A ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLON CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACRIMAL DUCT OCCLUSION; PRIORITY JOURNAL; SQUAMOUS CELL METAPLASIA; SYSTEMIC THERAPY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; EPITHELIAL CELLS; FEMALE; FLUOROURACIL; HUMANS; LACRIMAL APPARATUS; LACRIMAL DUCT OBSTRUCTION; METAPLASIA;

EID: 0036896428     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01290-3     Document Type: Article

References (16)

1. Curreri AR, Ansfield FJ, McIver FA, et al. Clinical studies with 5-fluorouracil. Cancer Res 1958;18:478-84.
2. Heidelberger C, Ansfield FJ. Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 1963;23:1226-43.
3. Caravella LP Jr, Burns JA, Zangmeister M. Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol 1981;99:284-6.
4. Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacry-ostenosis) due to 5-fluorouracil. Ann Intern Med 1978;88:657.
5. Lee V, Bentley CR, Olver JM. Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye 1998;12:343-9.
6. Fezza JP, Wesley RE, Klippenstein KA. The treatment of punctal and canalicular stenosis in patients on systemic 5-FU. Ophthalmic Surg Lasers 1999;30:105-8.
7. Hamersley J, Luce JK, Florentz TR, et al. Excessive lacrimation from fluorouracil treatment [letter]. JAMA 1973;225:747-8.
8. Bixenman WW, Nicholls JVV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977;83:789-93.
9. Bonadonna G, Brusamolino E. Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
10. Adams JW, Bofenkamp TM, Kobrin J, et al. Recurrent acute toxic optic neuropathy secondary to 5-FU [letter]. Cancer Treat Rep 1984;68:565-6.
11. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med 1974;291:75-81.
12. Straus DJ, Mausolf FA, Ellerby RA, McCracken JD. Cicatricial ectropion secondary to 5-fluorouracil therapy. Med Pediatr Oncol 1977;3:15-9.
13. Christophidis N, Vajda FJE, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. Aust N Z J Med 1979;9:143-4.
14. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (Taxotere). A newly recognized side effect. Ophthalmology 2001;108:994-5.
15. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 2001;119:1802-4.
16. Seiff SR, Shorr N, Adams T. Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy. Cancer 1985;56:2148-9.